BD Partners with Penn Institute to Advance Immunotherapy Research

Reuters12-18 19:50

BD Partners with Penn Institute to Advance Immunotherapy Research

BD (Becton, Dickinson and Company), a leading global medical technology company, has announced a strategic collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania. This partnership aims to advance research in deep human immune profiling and support the development of immune-mediated therapies. As part of the collaboration, BD’s FACSDiscover™ A8 Cell Analyzer will be used to investigate over 30 cellular characteristics, enabling comprehensive biological insights and supporting a planned 1,000-person immune profiling study. The joint effort includes developing and validating a high-parameter flow cytometry panel to capture key functional pathways in whole blood, offering powerful insights into immune system function.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BD - Becton, Dickinson and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: NY50232) on December 18, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592085859?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 19:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592085859","market":"fut","top_or_hot":-1,"title":"BD Partners with Penn Institute to Advance Immunotherapy Research","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BD Partners with Penn Institute to Advance Immunotherapy Research\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BD (Becton, Dickinson and Company), a leading global medical technology company, has announced a strategic collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania. This partnership aims to advance research in deep human immune profiling and support the development of immune-mediated therapies. As part of the collaboration, BD’s FACSDiscover™ A8 Cell Analyzer will be used to investigate over 30 cellular characteristics, enabling comprehensive biological insights and supporting a planned 1,000-person immune profiling study. The joint effort includes developing and validating a high-parameter flow cytometry panel to capture key functional pathways in whole blood, offering powerful insights into immune system function.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BD - Becton, Dickinson and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: NY50232) on December 18, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BD Partners with Penn Institute to Advance Immunotherapy Research</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBD Partners with Penn Institute to Advance Immunotherapy Research\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-18 19:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BD Partners with Penn Institute to Advance Immunotherapy Research\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BD (Becton, Dickinson and Company), a leading global medical technology company, has announced a strategic collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania. This partnership aims to advance research in deep human immune profiling and support the development of immune-mediated therapies. As part of the collaboration, BD’s FACSDiscover™ A8 Cell Analyzer will be used to investigate over 30 cellular characteristics, enabling comprehensive biological insights and supporting a planned 1,000-person immune profiling study. The joint effort includes developing and validating a high-parameter flow cytometry panel to capture key functional pathways in whole blood, offering powerful insights into immune system function.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BD - Becton, Dickinson and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: NY50232) on December 18, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1894683348.USD","symbol_name":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL5G1HT2:1","article_id":"2592085859","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592085859","pubTimestamp":1766058615,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BD , a leading global medical technology company, has announced a strategic collaboration with the Institute for Immunology and Immune Health  at the University of Pennsylvania. This partnership aims to advance research in deep human immune profiling and support the development of immune-mediated therapies. As part of the collaboration, BD’s FACSDiscover A8 Cell Analyzer will be used to investigate over 30 cellular characteristics, enabling comprehensive biological insights and supporting a planned 1,000-person immune profiling study. The joint effort includes developing and validating a high-parameter flow cytometry panel to capture key functional pathways in whole blood, offering powerful insights into immune system function.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","BK4588":"碎股","BDX":"碧迪医疗","LU0068578508.USD":"First Eagle Amundi International Cl AU-C USD","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","LU1201861165.SGD":"Natixis Harris Associates Global Equity PA SGD","LU1489326972.SGD":"First Eagle Amundi International AHS-MD SGD-H","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU1150488135.SGD":"First Eagle Amundi Income Builder AHS-MD SGD-H","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","LU0878866978.SGD":"First Eagle Amundi International AHS-QD SGD-H","LU0433182093.SGD":"First Eagle Amundi International AS-C SGD","LU0648000940.SGD":"Natixis Harris Associates Global Equity RA SGD","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","BK4585":"ETF&股票定投概念","LU1150488218.USD":"First Eagle Amundi Income Builder AU2-MD USD","LU0985489474.SGD":"First Eagle Amundi International AHS-C SGD-H","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","LU0130518102.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"R\" INC","LU0477156797.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"RE\" (USD) ACC","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","BK4082":"医疗保健设备","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4504":"桥水持仓"},"translate_title":"BD与宾夕法尼亚研究所合作推进免疫治疗研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BDX":0.9},"content_text":"BD Partners with Penn Institute to Advance Immunotherapy Research\n    \n\n        BD (Becton, Dickinson and Company), a leading global medical technology company, has announced a strategic collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania. This partnership aims to advance research in deep human immune profiling and support the development of immune-mediated therapies. As part of the collaboration, BD’s FACSDiscover™ A8 Cell Analyzer will be used to investigate over 30 cellular characteristics, enabling comprehensive biological insights and supporting a planned 1,000-person immune profiling study. The joint effort includes developing and validating a high-parameter flow cytometry panel to capture key functional pathways in whole blood, offering powerful insights into immune system function.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BD - Becton, Dickinson and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: NY50232) on December 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592085859","isCrawlerRequest":true}